Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team

Stablix Appoints Eddine Saiah Chief Scientific Officer and Expands Leadership Team

May 26, 2022 by Business Wire Health News

Key Facts

  • “Stablix’s recent presentation at the Induced Proximity-Based Drug Discovery Summit showing the ability of the platform to generate and validate heterobifunctional small molecules that induce the stabilization of selected proteins of interest gives me further conviction in the ability of our platform to generate an entirely new class of medicines.”

  • Earlier in his career, Dr. Saiah held a series of leadership roles in drug discovery at Pfizer and Wyeth, where he led multiple discovery and early clinical development teams, advancing over a dozen small molecule candidates into clinical trials with indications in inflammation and immunology, metabolic disease and rare disease.
  • A large number of proteins are aberrantly degraded in the cell leading to diseases such as genetic diseases, cancer and neurodegenerative diseases,” said Dr. Saiah.
  • “Stablix’s recent presentation at the Induced Proximity-Based Drug Discovery Summit showing the ability of the platform to generate and validate heterobifunctional small molecules that induce the stabilization of selected proteins of interest gives me further conviction in the ability of our platform to generate an entirely new class of medicines.”

Click To Read Full Article

PERSON
ORGANIZATION
GEOGRAPHY
WORK OF ART
EVENT
MONEY
MISCELLANEOUS

This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2021 Kwhen Inc.

Was this content valuable for you?